Literature DB >> 33477980

Impact of Antibiotics Associated with the Development of Toxic Epidermal Necrolysis on Early and Late-Onset Infectious Complications.

Bretislav Lipovy1,2, Jakub Holoubek1, Marketa Hanslianova3, Michaela Cvanova4, Leo Klein5,6, Ivana Grossova7, Robert Zajicek7, Peter Bukovcan8, Jan Koller8, Matus Baran9, Peter Lengyel9, Lukas Eimer10, Marie Jandova11, Milan Kostal12, Pavel Brychta1, Petra Borilova Linhartova13,14,15,16,17.   

Abstract

Toxic epidermal necrolysis (TEN) is a rare disease, which predominantly manifests as damage to the skin and mucosa. Antibiotics count among the most common triggers of this hypersensitive reaction. Patients with TEN are highly susceptible to infectious complications due to the loss of protective barriers and immunosuppressant therapy. The aim of this study was to investigate the potential relationship between antibiotics used before the development of TEN and early and late-onset infectious complications in TEN patients. In this European multicentric retrospective study (Central European Lyell syndrome: therapeutic evaluation (CELESTE)), records showed that 18 patients with TEN used antibiotics (mostly aminopenicillins) before the disease development (group 1), while in 21 patients, TEN was triggered by another factor (group 2). The incidence of late-onset infectious complications (5 or more days after the transfer to the hospital) caused by Gram-positive bacteria (especially by Enterococcus faecalis/faecium) was significantly higher in group 1 than in group 2 (82.4% vs. 35.0%, p = 0.007/p corr = 0.014) while no statistically significant difference was observed between groups of patients with infection caused by Gram-negative bacteria, yeasts, and filamentous fungi (p > 0.05). Patients with post-antibiotic development of TEN are critically predisposed to late-onset infectious complications caused by Gram-positive bacteria, which may result from the dissemination of these bacteria from the primary focus.

Entities:  

Keywords:  antibiotics; early-onset infection; infectious complication; late-onset infection; toxic epidermal necrolysis

Year:  2021        PMID: 33477980      PMCID: PMC7835845          DOI: 10.3390/microorganisms9010202

Source DB:  PubMed          Journal:  Microorganisms        ISSN: 2076-2607


  68 in total

1.  SCORTEN: a severity-of-illness score for toxic epidermal necrolysis.

Authors:  S Bastuji-Garin; N Fouchard; M Bertocchi; J C Roujeau; J Revuz; P Wolkenstein
Journal:  J Invest Dermatol       Date:  2000-08       Impact factor: 8.551

2.  Toxic epidermal necrolysis: five years of treatment experience from a burn unit.

Authors:  Bahar F Firoz; Jeffrey Scott Henning; Lee Ann Zarzabal; Brad H Pollock
Journal:  J Am Acad Dermatol       Date:  2012-01-27       Impact factor: 11.527

Review 3.  Treatment of toxic epidermal necrolysis by a multidisciplinary team. A review of literature and treatment results.

Authors:  Anthony Papp; Sheena Sikora; Morgan Evans; Diana Song; Mark Kirchhof; Monica Miliszewski; Jan Dutz
Journal:  Burns       Date:  2018-04-04       Impact factor: 2.744

Review 4.  Toxic epidermal necrolysis.

Authors:  Florence Castelain; Philippe Humbert
Journal:  Curr Drug Saf       Date:  2012-11-01

5.  A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century.

Authors:  T L Palmieri; D G Greenhalgh; J R Saffle; R J Spence; M D Peck; J C Jeng; D W Mozingo; C J Yowler; R L Sheridan; D H Ahrenholz; D M Caruso; K N Foster; R J Kagan; D W Voigt; G F Purdue; J L Hunt; S Wolf; F Molitor
Journal:  J Burn Care Rehabil       Date:  2002 Mar-Apr

Review 6.  A Review of the Active Treatments for Toxic Epidermal Necrolysis.

Authors:  Yuri Kinoshita; Hidehisa Saeki
Journal:  J Nippon Med Sch       Date:  2017       Impact factor: 0.920

Review 7.  Guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis: An Indian perspective.

Authors:  Lalit Kumar Gupta; Abhay Mani Martin; Nidheesh Agarwal; Paschal D'Souza; Sudip Das; Rajesh Kumar; Sushil Pande; Nilay Kanti Das; Muthuvel Kumaresan; Piyush Kumar; Anubhav Garg; Saurabh Singh
Journal:  Indian J Dermatol Venereol Leprol       Date:  2016 Nov-Dec       Impact factor: 2.545

Review 8.  Responsiveness to i.v. immunoglobulin therapy in patients with toxic epidermal necrolysis: A novel pharmaco-immunogenetic concept.

Authors:  Petra Borilova Linhartova; Daniela Gachova; Bretislav Lipovy
Journal:  J Dermatol       Date:  2020-09-15       Impact factor: 4.005

9.  Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study.

Authors:  Maja Mockenhaupt; Cecile Viboud; Ariane Dunant; Luigi Naldi; Sima Halevy; Jan Nico Bouwes Bavinck; Alexis Sidoroff; Jürgen Schneck; Jean-Claude Roujeau; Antoine Flahault
Journal:  J Invest Dermatol       Date:  2007-09-06       Impact factor: 8.551

10.  Incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis among new users of different individual drugs in a European population: a case-population study.

Authors:  Sara Rodríguez-Martín; Elisa Martín-Merino; Victoria Lerma; Antonio Rodríguez-Miguel; Olga González; Carlos González-Herrada; Elena Ramírez; Teresa Bellón; Francisco J de Abajo
Journal:  Eur J Clin Pharmacol       Date:  2018-10-08       Impact factor: 2.953

View more
  1 in total

1.  Toxic epidermal necrolysis in hepatitis A infection with acute-on-chronic liver failure: Case report and literature review.

Authors:  Xin Zang; Si Chen; Lin Zhang; Yongzhen Zhai
Journal:  Front Med (Lausanne)       Date:  2022-09-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.